Skip to main navigation Skip to search Skip to main content

Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol

  • Jordana B. Cohen
  • , Thomas C. Hanff
  • , Vicente Corrales-Medina
  • , Preethi William
  • , Nicolas Renna
  • , Nelson R. Rosado-Santander
  • , Juan E. Rodriguez-Mori
  • , Jonas Spaak
  • , Jaime Andrade-Villanueva
  • , Tara I. Chang
  • , Alejandro Barbagelata
  • , Carlos E. Alfonso
  • , Eduardo Bernales-Salas
  • , Johanna Coacalla
  • , Carlos Augusto Castro-Callirgos
  • , Karen E. Tupayachi-Venero
  • , Carola Medina
  • , Renzo Valdivia
  • , Mirko Villavicencio
  • , Charles R. Vasquez
  • Michael O. Harhay, Jesse Chittams, Tiffany Sharkoski, James Brian Byrd, Daniel L. Edmonston, Nancy Sweitzer, Julio A. Chirinos

Research output: Contribution to journal › Article › peer-review

Original languageEnglish
Pages (from-to)1780-1788
Number of pages9
JournalJournal of Clinical Hypertension
Volume22
Issue number10
DOIs
StatePublished - Oct 1 2020
Externally publishedYes

ASJC Scopus Subject Areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Keywords

  • angiotensin receptor blocker
  • angiotensin-converting enzyme inhibitor
  • angiotensin-converting enzyme inhibitor 2
  • clinical trial
  • coronavirus
  • COVID-19
  • hypertension

Cite this